Company intelligence / Profile preview
Chiome Bioscience Inc.
Tokyo (Shibuya-ku), Tokyo Prefecture, Japanchiome.co.jp ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Chiome Bioscience Inc. specializes in developing therapeutic monoclonal antibodies using proprietary platforms such as the ADLib® system. The company focuses on both internal drug discovery and providing development support services to pharmaceutical partners. It has a pipeline targeting novel antigens with an emphasis on oncology/immuno-oncology applications. Recent reports include progress in cancer immunotherapy research.
- Therapeutic areas
- OtherOncology
- Modalities
- Monoclonal antibodies (mAbs)Multi-specific antibodiesRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
03
Partnerships
Collaborates with pharmaceutical companies domestically and internationally for lead antibody development and licensing; specific partners not listed by name.
Beyond the preview
Go deeper on Chiome Bioscience Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chiome Bioscience Inc..